Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

ProKidney Establishes Guilford County, North Carolina, Biomanufacturing Facility

06/15/2023
ProKidney Corp., a late clinical-stage cellular therapeutics company focused on chronic kidney disease, will be establishing a new biomanufacturing facility in Greensboro, North Carolina. The $485 million project is expected to create 330 jobs in Guilford County.

The investment will include a 210,000-square-foot manufacturing facility at the 73 Business Center and will allow the company to prepare for future commercial manufacturing of REACT® (REnal Autologous Cell Therapy), the company’s lead product candidate being developed for the treatment of chronic kidney disease.

“We considered many factors in determining where best to build future commercial manufacturing capacity for REACT,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Because of North Carolina’s depth and breadth of biotechnology talent, the advantage of locating the plant near our headquarters and pilot manufacturing plant in Winston-Salem, NC, and the state’s interest in continuing to grow its biotechnology industry, we determined that adding manufacturing capacity here in Greensboro would be in the best interest of ProKidney, its shareholders and its local stakeholders. We look forward to continue growing our business along with the state that we have called home since our founding.”

ProKidney’s project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state’s Economic Investment Committee. Over the course of the 12-year term of this grant, the project is estimated to grow the state’s economy by $1.7 billion. Using a formula that takes into account the new tax revenues generated by the 330 new jobs, along with a company investment of $485 million, the JDIG agreement authorizes the potential reimbursement to the company of up to $5,132,700, spread over 12 years.

State payments only occur following performance verification by the departments of Commerce and Revenue that the company has met its incremental job creation and investment targets. JDIG projects result in positive net tax revenue to the state treasury, even after taking into consideration the grant’s reimbursement payments to a given company.

“As a former executive in the biotech industry, I’m proud to see North Carolina’s continued leadership in this industry, which means so much for both our economy and for people’s health and wellbeing,” noted North Carolina Commerce Secretary Machelle Baker Sanders. “We never take for granted the importance of a strong, well-trained workforce to keep us ahead of the pack. As our First in Talent strategic plan makes clear, we’ll continue to invest in our people and the educational systems that create opportunities for everyone.”

Because ProKidney chose a site in Guilford County, classified by the state’s economic tier system as Tier 2, the company’s JDIG agreement also calls for moving $570,300 into the state’s Industrial Development Fund – Utility Account. The Utility Account helps rural communities finance necessary infrastructure upgrades to attract future business. Even when new jobs are created in a Tier 2 county such as Guilford, the new tax revenue generated through JDIG grants helps more economically challenged communities elsewhere in the state.

“We are thrilled that a homegrown company like ProKidney will continue its game-changing work in North Carolina,” added Christopher Chung, CEO of the EDPNC. “North Carolina’s highly trained workforce, top-notch education systems and public and private partnerships offer what companies like ProKidney need to be innovative and successful.”

ProKidney, headquartered in Winston-Salem, is a pioneer in the development of a cell-based treatment for CKD. The company’s lead product candidate, REACT, is a first-of-its-kind, patented, proprietary therapy with the potential to preserve kidney function in patients at high risk of kidney failure. ProKidney’s approach utilizes a patient’s own kidney cells in the treatment process.

Partnering with the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina (EDPNC) on this project were the North Carolina General Assembly, the North Carolina Community College System, the North Carolina Department of Transportation, the North Carolina Biotechnology Center, Duke Energy, Guilford Technical Community College, Guilford County, the City of Greensboro, the Guilford County Economic Development Alliance, and the Greensboro Chamber of Commerce.

Exclusive Research